Abstract:Bladder cancer in the most advanced, muscle-invasive stage is lethal, and very limited therapeutic advances have been reported for decades. To date, cisplatin-based chemotherapy remains the first-line therapy for advanced bladder cancer. Late-line options have historically been limited. In the past few years, next-generation sequencing technology has enabled chromatin remodelling gene mutations to be characterized, showing that these alterations are more frequent in urothelial bladder carcinoma than in other cancer types. Histone modifiers have functional roles in tumour progression by modulating the expression of tumour suppressors and oncogenes and, therefore, have been considered as novel drug targets for cancer therapy. The roles of epigenetic reprogramming through histone modifications have been increasingly studied in bladder cancer, and the therapeutic efficacy of targeting those histone modifiers genetically or chemically is being assessed in preclinical studies. Results from preclinical studies in bladder cancer encouraged the investigation of some of these drugs in clinical trials, which yield mixed results. Further understanding of how alterations of histone modification mechanistically contribute to bladder cancer progression, drug resistance and tumour microenvironment remodelling will be required to facilitate clinical application of epigenetic drugs in bladder cancer.

Targeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

The Roles of Chromatin Remodeling Proteins in Cancer

Epigenomic regulation of oncogenesis by chromatin remodeling

Therapeutic index of targeting select chromatin complexes in human cancer patients

Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer

The therapeutic potential of targeting the CHD protein family in cancer

Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment

Technologies for Targeting DNA Methylation Modifications: Basic Mechanism and Potential Application in Cancer.

Targeting chromatin complexes in fusion protein-driven malignancies

Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs

The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer

Targeting Post-Translational Modification of Transcription Factors As Cancer Therapy.

Targeting Key Proteins Involved in Transcriptional Regulation for Cancer Therapy: Current Strategies and Future Prospective.

Molecular Mechanisms of Epigenetic Regulators As Activatable Targets in Cancer Theranostics.

Metabolic reprogramming and epigenetic modifications on the path to cancer

Cellular Reprogramming as a Therapeutic Target in Cancer

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Targeting histone modifiers in bladder cancer therapy — preclinical and clinical evidence

Therapeutic Discovery for Chromatin Complexes: Where Do We Stand?